2022 JUN 01 (NewsRx) — By a News Reporter-Staff News Editor at Insurance Daily News — New research on Public Health – Vaccination is the subject of a report. According to news reporting from Paris, France, by NewsRx journalists, research stated, “Invasive meningococcal disease (IMD) carries a high burden in terms of mortality, long-term complications, and cost, which can be significantly reduced by vaccination. The objectives of this case-control study were to document the care pathways of patients with IMD before, during, and after hospitalization and to assess in-hospital complications and long-term sequelae.”
Financial supporters for this research include GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SA.
The news correspondents obtained a quote from the research from Pasteur Institute, “Cases consisted of all people hospitalized for IMD in France between 2012 and 2017. Controls were matched by age, gender, and district of residence. Data were extracted from the French national public health insurance database on demographics, hospitalizations, mortality and potential sequelae of IMD. Overall, 3,532 cases and 10,590 controls were assessed and followed up for 2.8 years (median). During hospitalization, 1,577 cases (44.6%) stayed in an intensive care unit, 1,238 (35.1%) required mechanical ventilation, and 43 (1.2%) underwent amputation; 293 cases (8.3%) died in hospital and a further 163 (4.6%) died following discharge; 823 cases (25.4% of survivors) presented 1 sequela and 298 (9.2%) presented multiple sequelae. The most frequently documented sequelae were epilepsy (N = 205; 5.8%), anxiety (N = 196; 5.5%), and severe neurological disorders (N = 193; 5.5%). All individual sequelae were significantly more frequent (< .0001) in cases than controls. Hearing/visual impairment and communication problems were conditions that presented the highest risk for cases compared to controls (risk ratios >20 in all cases).”
According to the news reporters, the research concluded: “This study highlights the importance of providing optimal medical care for patients with IMD, of minimizing the delay before hospitalization, and of effective prevention through comprehensive vaccination programs.”
This research has been peer-reviewed.
For more information on this research see: Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Human Vaccines & Immunotherapeutics, 2022;18(1):2021764. Human Vaccines & Immunotherapeutics can be contacted at: Taylor & Francis Inc, 530 Walnut Street, Ste 850, Philadelphia, PA 19106, USA.
Our news journalists report that additional information may be obtained by contacting Muhamed-Kheir Taha, Invasive Bacterial Infections Unit, Pasteur Institute, Paris, France. Additional authors for this research include Catherine Weil-Olivier, Stephane Bouee, Corinne Emery, Veronique Loncle-Provot, Gaelle Nachbaur, Ekkehard Beck and Celine Pribil.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1080/21645515.2021.2021764. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Publisher contact information for the journal Human Vaccines & Immunotherapeutics is: Taylor & Francis Inc, 530 Walnut Street, Ste 850, Philadelphia, PA 19106, USA.
(Our reports deliver fact-based news of research and discoveries from around the world.)